Literature DB >> 28839974

Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease.

Wilbert S Aronow1.   

Abstract

Entities:  

Year:  2017        PMID： 28839974      PMCID： PMC5542999          DOI： 10.21037/jtd.2017.06.106

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  21 in total

Review 1.  High-density lipoprotein as a therapeutic target: a systematic review.

Authors:  Inder M Singh; Mehdi H Shishehbor; Benjamin J Ansell
Journal:  JAMA       Date:  2007-08-15       Impact factor: 56.272

Review 2.  Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

3.  Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease.

Authors:  W S Aronow; C Ahn
Journal:  Am J Cardiol       Date:  1996-04-15       Impact factor: 2.778

4.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

5.  Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.

Authors:  S Zhong; D S Sharp; J S Grove; C Bruce; K Yano; J D Curb; A R Tall
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

6.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

Review 7.  Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk.

Authors:  Alexander Thompson; Emanuele Di Angelantonio; Nadeem Sarwar; Sebhat Erqou; Danish Saleheen; Robin P F Dullaart; Bernard Keavney; Zheng Ye; John Danesh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

8.  Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Authors:  Gregory G Schwartz; Anders G Olsson; Markus Abt; Christie M Ballantyne; Philip J Barter; Jochen Brumm; Bernard R Chaitman; Ingar M Holme; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Hardi Mundl; Stephen J Nicholls; Prediman K Shah; Jean-Claude Tardif; R Scott Wright
Journal:  N Engl J Med       Date:  2012-11-05       Impact factor: 91.245

9.  Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.

Authors:  Philip J Barter; Stephen J Nicholls; John J P Kastelein; Kerry-Anne Rye
Journal:  Circulation       Date:  2015-08-04       Impact factor: 29.690

10.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.